news
AI Repurposes Old Drugs, But Getting Them to Patients is Hard
AI can scan existing drugs for new uses, especially for rare diseases, says Bio-IT World. Every Cure founder David Fajgenbaum highlights the challenge of translating these computational predictions into actual treatments for patients. It's a pipeline problem: finding a new drug use is one thing, getting it through trials and regulatory hurdles is another entirely.
AI can scan existing drugs for new uses, especially for rare diseases, says Bio-IT World. Every Cure founder David Fajgenbaum highlights the challenge of translating these computational predictions into actual treatments for patients. It's a pipeline problem: finding a new drug use is one thing, getting it through trials and regulatory hurdles is another entirely.
The architecture take
This idea of AI finding new jobs for old drugs for rare diseases? It feels like hitting the jackpot without knowing if the machine works. We're great at identifying molecules that could, theoretically, tweak a body system or two. The actual hurdle isn't the discovery; it's the clinical validation. That takes time, money, and human patience, none of which AI offers. What this really tells me is the medical world has a lot of tools that work, but we're still slow to iterate on them. Your body is a complex system, and changing one part often means unintended consequences. Getting a drug from an algorithm to your actual cells means testing, dosing, and confirming safety in a way that code just can't simulate. So, while the promise is there, the bottleneck is still human biology and regulatory friction.